Cowen and Company reissued their buy rating on shares of Edwards Lifesciences Corporation (NYSE:EW) in a research note published on Thursday. The brokerage currently has a $135.00 price objective on the medical research company’s stock.

Several other equities research analysts have also commented on the company. SunTrust Banks, Inc. upped their price objective on Edwards Lifesciences Corporation to $14.00 and gave the stock a buy rating in a research note on Monday, July 17th. Jefferies Group LLC restated a buy rating and issued a $115.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Friday, June 30th. Canaccord Genuity restated a buy rating and issued a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Stifel Nicolaus restated a buy rating and issued a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Bank of America Corporation upped their price objective on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a buy rating in a research note on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Edwards Lifesciences Corporation has an average rating of Buy and a consensus target price of $120.75.

Shares of Edwards Lifesciences Corporation (NYSE EW) traded down 1.77% during trading on Thursday, reaching $108.25. The company’s stock had a trading volume of 1,446,300 shares. The company has a market capitalization of $22.86 billion, a price-to-earnings ratio of 32.83 and a beta of 0.62. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.45. The firm’s 50-day moving average price is $111.37 and its 200-day moving average price is $111.44.

Edwards Lifesciences Corporation (NYSE:EW) last announced its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. The business had revenue of $842.00 million during the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.76 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

WARNING: This news story was first reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/10/15/edwards-lifesciences-corporation-ew-earns-buy-rating-from-cowen-and-company.html.

In other Edwards Lifesciences Corporation news, VP Catherine M. Szyman sold 4,681 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total transaction of $541,966.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $114.80, for a total transaction of $3,776,920.00. The disclosure for this sale can be found here. Insiders have sold a total of 182,201 shares of company stock valued at $20,768,154 in the last three months. Insiders own 2.13% of the company’s stock.

Large investors have recently made changes to their positions in the stock. ETF Managers Group LLC bought a new position in shares of Edwards Lifesciences Corporation in the 2nd quarter valued at about $112,000. Shine Investment Advisory Services Inc. bought a new position in shares of Edwards Lifesciences Corporation in the 2nd quarter valued at about $126,000. Cornerstone Advisors Inc. lifted its holdings in shares of Edwards Lifesciences Corporation by 25.1% in the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 219 shares during the last quarter. Alexandria Capital LLC lifted its holdings in shares of Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 19 shares during the last quarter. Finally, MPS Loria Financial Planners LLC bought a new position in shares of Edwards Lifesciences Corporation in the 2nd quarter valued at about $140,000. 82.12% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.